top of page

Philadelphia area based XyloCor is developing a gene therapy with the goal of helping to revascularize the heart for refractory angina patients

  • Jul 25, 2024
  • 1 min read

CEO Al Gianchetti explains that the company recently released final results from a phase 1/2 clinical trial and how XyloCor is set to begin a new study utilizing a catheter system that does not require open heart surgery for delivery.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page